Cantor Fitzgerald slashes price target on Ardelyx Inc. [ARDX] – find out why.

Related

Ardelyx Inc. [NASDAQ: ARDX] price surged by 8.69 percent to reach at $0.06. The company report on June 3, 2022 that Ardelyx to Present at the Jefferies 2022 Healthcare Conference.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022, at 8:30 a.m. ET in New York City.

To access the live webcast of Ardelyx’s presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 30 days following the conference.

A sum of 4085511 shares traded at recent session while its average daily volume was at 3.23M shares. Ardelyx Inc. shares reached a high of $0.718 and dropped to a low of $0.6295 until finishing in the latest session at $0.70.

The one-year ARDX stock forecast points to a potential upside of 85.01. The average equity rating for ARDX stock is currently 1.90, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Ardelyx Inc. [ARDX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARDX shares is $4.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARDX stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for Ardelyx Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 06, 2022. The new note on the price target was released on December 01, 2021, representing the official price target for Ardelyx Inc. stock. On July 21, 2021, analysts decreased their price target for ARDX shares from 11 to 2.

The Average True Range (ATR) for Ardelyx Inc. is set at 0.07, with the Price to Sales ratio for ARDX stock in the period of the last 12 months amounting to 24.10. The Price to Book ratio for the last quarter was 1.42, with the Price to Cash per share for the same quarter was set at 0.65.

ARDX Stock Performance Analysis:

Ardelyx Inc. [ARDX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.99. With this latest performance, ARDX shares dropped by -14.13% in over the last four-week period, additionally sinking by -49.59% over the last 6 months – not to mention a drop of -90.28% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARDX stock in for the last two-week period is set at 49.47, with the RSI for the last a single of trading hit 55.17, and the three-weeks RSI is set at 47.06 for Ardelyx Inc. [ARDX]. The present Moving Average for the last 50 days of trading for this stock 0.8110, while it was recorded at 0.6541 for the last single week of trading, and 1.0294 for the last 200 days.

Insight into Ardelyx Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Ardelyx Inc. [ARDX] shares currently have an operating margin of -1528.63 and a Gross Margin at +45.27. Ardelyx Inc.’s Net Margin is presently recorded at -1566.46.

Return on Equity for this stock declined to -151.55, with Return on Assets sitting at -90.00.

Ardelyx Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.30 and a Current Ratio set at 2.40.

ARDX Stock EPS

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ARDX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ardelyx Inc. go to 30.00%.

Ardelyx Inc. [ARDX] Insider Position Details

There are presently around $26 million, or 28.80% of ARDX stock, in the hands of institutional investors. The top three institutional holders of ARDX stocks are: BLACKROCK INC. with ownership of 5,700,576, which is approximately 1.272% of the company’s market cap and around 1.80% of the total institutional ownership; GREAT POINT PARTNERS I LP, holding 4,761,905 shares of the stock with an approximate value of $3.05 million in ARDX stocks shares; and VANGUARD GROUP INC, currently with $2.52 million in ARDX stock with ownership of nearly -11.19% of the company’s market capitalization.

40 institutional holders increased their position in Ardelyx Inc. [NASDAQ:ARDX] by around 9,747,702 shares. Additionally, 55 investors decreased positions by around 11,649,790 shares, while 21 investors held positions by with 18,951,837 shares. The mentioned changes placed institutional holdings at 40,349,329 shares, according to the latest SEC report filing. ARDX stock had 14 new institutional investments in for a total of 5,372,784 shares, while 26 institutional investors sold positions of 6,432,160 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]